● Home  

● Random  

● Nearby  



● Log in  



● Settings  



● Donate  



● About Wikipedia  

● Disclaimers  



Wikipedia





Lotiglipron





● Article  
● Talk  


● Language  

● Watch  

● Edit  





Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drugbyPfizer.[1] It was withdrawn from development after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.[2]

Lotiglipron
Identifiers

  • 2-{[4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl]methyl}-3-{[(2S)-oxetan-2-yl]methyl}benzimidazole-5-carboxylic acid

CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC31H31ClN4O5
Molar mass575.06 g·mol−1
3D model (JSmol)

  • C[C@@]1(OC2=CC=CC(=C2O1)C3CCN(CC3)CC4=NC5=C(N4C[C@@H]6CCO6)C=C(C=C5)C(=O)O)C7=NC=C(C=C7)Cl

  • InChI=1S/C31H31ClN4O5/c1-31(27-8-6-21(32)16-33-27)40-26-4-2-3-23(29(26)41-31)19-9-12-35(13-10-19)18-28-34-24-7-5-20(30(37)38)15-25(24)36(28)17-22-11-14-39-22/h2-8,15-16,19,22H,9-14,17-18H2,1H3,(H,37,38)/t22-,31-/m0/s1

  • Key:SVPYZAJTWFQTSM-UGDMGKLASA-N

See also

edit

References

edit
  1. ^ US 10676465, Aspnes GE, et al., "GLP-1 receptor agonists and uses thereof", issued 9 June 2020, assigned to Pfizer Inc 
  • ^ Griffin M (26 June 2023). "Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns". Time.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Lotiglipron&oldid=1188878182"
      



    Last edited on 8 December 2023, at 06:48  





    Languages

     


    ●فارسی
      

     Wikipedia


    ●This page was last edited on 8 December 2023, at 06:48 (UTC).
    ●Content is available under CC BY-SA 4.0 unless otherwise noted.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Terms of Use
    ●Desktop